BRAF wild-type

Intermittent or continuous FOLFIRI/PANI for 1st line RAS/BRAF WT mCRC: update of survival/toxicity & preliminary results of GA from IMPROVE @ #WCGIC2023 👉Stop & go seems feasible, less toxicity 👉Resistente mechanisms not yet resolved @WCGIC @myESMO @OncoAlert (@ArndtVogel)

Intermittent or continuous FOLFIRI/PANI for 1st line RAS/BRAF WT mCRC: update of survival/toxicity & preliminary results of GA from IMPROVE @ #WCGIC2023 👉Stop & go seems feasible, less toxicity 👉Resistente mechanisms not yet resolved @WCGIC @myESMO @OncoAlert (@ArndtVogel)

We're excited for Dr. Alfonso De Stefano's (@alfdestefano) presentation on "Intermittent or continuous panitumumab + FOLFIRI for first-line treatment of patients with RAS/BRAF wild type metastatic #ColorectaLCancer" at #WCGIC2023 tomorrow! 🤩 Program: https://t.co/ln4c4FaZ9J (@Intestinal_Cell)

Quali update sulla terapia di mantenimento con #cetuximab del #CRC RAS BRAF wild type? Quali pazienti possono beneficiarne maggiormente? Risponde C.Pinto in un’intervista, a breve sul secondo numero speciale post #ASCO23 di Oncoinfo Ecco un assaggio! 👇🏼 #carcinomacolonretto (@Oncoinfo_it)

Just out on Cancer Medicine 📢 Rechallenge with EGFRi based therapy as 3 line treatment in RAS/BRAF wt mCRC: IPD pooled analysis of the CAVE and CRICKET trials. @Giulia_Martini1 @grikamartinelli @FilippoPietran4 @ChiaraCrem1 @napolitano_ste https://t.co/lPdOKkrN7r (@DCiardiello)

1) Prof Toni Ribas @UCLAJCCC presentation on trial for pts with #melanoma who are #BRAF WT & failed #PD1/combo with #Ipi /PRACTICE CHANGING! / @SU2C #SU2CSummit2023 @bmsnews @CampKatiee / great monitoring!! (@BernardAFox)

Great JC by @nehahipp on #M14TIL @NEJM trial for #TIL vs Ipi in 2nd line adv #melanoma ➡️ 55% BRAF wild-type ➡️ PFS 7.2mo (TIL) vs 3.1mo (ipi) ➡️ OS 26mo vs 19mo (not powered) ➡️ AEs: 💧🫁🤒🩸… ➡️ Issues: pt selection, banking, bridging, $$, access outside of TIL out of trial (@DrKarineTawagi)

BRAF WT melanoma (@SMImmunology)

Getting #MedTwitter input on your choice of frontline antibody for Left sided RAS/BRAF WT mCRC @ILSONDavid @CathyEngMD @VanMorrisMD @aparna1024 @DocDustyD @AndreaCercek @Dr_M_Tejani @PMBolandMD @KristenCiombor @MayCho_MD @FoxChaseCancer #GDGI22 (@NVijayvergiaMD)

Christine Parseghian, MD, reviewed a phase 2 trial assessing efficacy of panitumumab +/- trametinib in patients with RAS/BRAF wild-type #crcsm vs EGFR rechallenge strategies with available agents in the third-line setting. @ParseghianC @MDAndersonNews https://t.co/63chbpdUXu (@CancerNetwrk)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, & Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO https://t.co/aEsK3oRWiT (@weldeiry)

🎥 @ChiaraCrem1 of @Unipisa talks on mFOLFOXIRI/PAN vs mFOLFOX6/PAN as initial treatment of patients with unresectable RAS & BRAF WT mCRC Watch: 👉https://t.co/ZJdFC9j2yS👈 @ASCO #ASCO22 (@VJOncology)

2/2 This is the first comprehensive report on the spontaneous MSI / BRAF WT #crcsm population with more targetable fusion events: https://t.co/nzex00gHcx (@BenWestphalen)

1/2 With regards to finding #crcsm MSI NTRK ✅ patients ⬇️ ‼️They are almost exclusively spontaneous (non Lynch) BRAF WT MSI.‼️ ⬆️And this population enriches for other targetable fusion events (see next post). https://t.co/ZUTIK3ZEGE (@BenWestphalen)

65 y/o woman w/ mCRC, L sided, RAS WT, MSI-S, BRAF WT, HER 2 Neu +ve, s/p mFOLFOX+Pan and FOLFIRI + Bev, wt would u recommend as 3L in the community outside clinical trial? Is Ph2 data good enough? Sequencing? #GISM #OncTwitter @pashtoonkasi @marklewismd @GillSharlene @myESMO (@OncBrothers)

How a hematologist thinks of colon cancer Stage 1= Mass invades Rx = Cut out 2 = Mass invades deeper (muscularis propria) Rx = Cut out 3 = +Nodes Rx= Cut out+adjuvant chemo 4= Metastatic Rx: MSI-H= anti-PD1 RAS/BRAF WT+left sided = chemo+EGFR AB Other= chemo+/-anti-VEGF (@AaronGoodman33)

Dear @pashtoonkasi @IbrahimSahinMD1 @VivekSubbiah do you think homologous recombination deficiency (POLE & POLD1 LOH) in TMB-L MSS RAS/BRAF WT mCRC could be targeted? I understand it's rare and it hasn't been studied. Any data/experience would be very appreciated. TY in any case! (@cancertrapped)

All else being equal, prognosis is best for 1) dMMR colorectal cancer and 2) left-sided KRAS/NRAS/BRAF wild-type without HER2 overexpression. But - prognosis is not destiny. Every situation is different. (@gabe_a_brooks)

Correct - upfront EGFR inhibitor is for left-sided, KRAS/NRAS/BRAF-wild type colorectal cancer without HER-2 overexpression - kind of a mouthful (@gabe_a_brooks)

👌presentation @ChiaraCrem1 #ASCO22 Triplette, but ❌no benefit in any study endpoint with folfoxiri +pan c/w folfox +pan in 1st line ras/braf wt mCRC Incl metastatic resection rates differ from volfi phase 2 ❓lower dose of FU in experimental arm ✅folfoxiri/pan not SOC (@JenSeligmann)

#TRIPLETE #asco22 @OncoAlert mFOLFOXIRI+PANI did not improve ORR (73% vs 76%, p=0.526) in RAS BRAF wt mCRC patients Kudos to @ChiaraCrem1 for her huge leadership and the great presentation 👏🏼 (@clacardone)

Oligometastatic Colorectal Cancer: A Personalized Approach #ASCO22 #CRCSM @OncoAlert Germline Lynch-PMS2 mut, tumor was WT RAS /BRAF WT Sequencing of tx? Chemo, RT & surgery☑️ Start with RT☑️ Start with chemo, since st 4 If symptomatic, start SCRT, not LCRT (@manjuggm)

Are we forgetting about New EPOC? @ChiaraCrem1 reminds us that patients in that trial were originally deemed to have resectable disease so we can more conscionably offer anti-EGFR in 1st line L-sided RAS/BRAF wt, MSS colon cancer if we do not anticipate surgery #ASCO22 #crcsm (@marklewismd)

#ASCO22 @CCAlliance @coloncancergal Discussion of treatment of newly diagnosed RAS and BRAF wt mCRC @smitha42 some results practice changing (@DrLauraPorter)

@ChiaraCrem1 PhIII TRIPLETE RAS/BRAF WT #mCRC (88% L-sided) #1L FOLFOXIRI-pmab (2400 5-FU, 150 irino) no sig diff in primary endpt ORR or R0 rate vs FOLFOX-pmab = when use of targeted agents in molecularly selected pop no benefit of intensification of chemo @OncoAlert #asco22 (@jgong15)

mFOLFOXIRI plus pani (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III TRIPLETE trial by GONO. Talk by Dr @ChiaraCrem1 #ASCO22 #CRCSM @OncoAlert (@manjuggm)

In her PARADIGM plenary discussion @ChiaraCrem1 (who is OWNING #ASCO22 podiums by the way) observed a ~3.5 month *loss* of median OS with bev first in 1st line L-sided ras/braf wt, MSS colon cancer (@marklewismd)

mFOLFOXIRI plus pani (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III TRIPLETE trial by GONO. Talk by Dr @ChiaraCrem1 #ASCO22 #CRCSM @OncoAlert (@manjuggm)

mFOLFOXIRI plus pani (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III TRIPLETE trial by GONO. Talk by Dr @ChiaraCrem1 #ASCO22 #CRCSM @OncoAlert (@manjuggm)

PhIII STRATEGIC-1 in #1L RAS/BRAF WT #mCRC (80% L-sided) sequence of (A) FOLFIRI-cmab->FOLFOX-bev vs (B) OPTIMOX-bev->FOLFIRI-bev->anti-EGFR mAb shows no sig diff in duration of disease control (primary endpt) and OS w/either seq (numerically higher w/arm A) @OncoAlert #ASCO22 (@jgong15)

#ASCO2022 We just presented IMPROVE study results : Intermittent FOLFIRI/PANITUMUMAB in RAS/BRAF wt unresectable mCRC showed a mPFS on treatment of 17.1 vs 13.2 (20.2 vs 13 in left sided) months vs standard continous exposure, with less skin related toxicities #crcsm @AvalloneAnt (@AlfredoBudillon)

mFOLFOXIRI plus pani (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III TRIPLETE trial by GONO. Talk by Dr @ChiaraCrem1 #ASCO22 #CRCSM @OncoAlert (@manjuggm)

Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study. Talk by Dr. Antonio Avallone, MD #ASCO22 #CRCSM (@manjuggm)

Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study. Talk by Dr. Antonio Avallone, MD #ASCO22 #CRCSM Very interesting.. (@manjuggm)

Dr. Avallone w/ the IMPROVE study: Intermittent vs continuous FOLFIRI/pani for 1L RAS/BRAF wt mCRC. 83-85% L sided tumors. PFSOT (on treatment) was 12.6 vs 17.6 months with 1 year PFSOT of 51.7 vs 61.3%. Looks like L sided benefits, R does not. #ASCO22 (@ryanhuey)

PhII IMPROVE in RAS/BRAF WT #mCRC positive and shows #1L intermittent FOLFIRI-pmab (X8 cycles then resumption upon PD) having improved on-tx 1-yr PFS in L-sided tumors, better skin toxicity than continuous FOLFIRI-pmab OS data not mature #ASCO22 @OncoAlert (@jgong15)

Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study. Talk by Antonio Avallone, MD #ASCO22 #CRCSM (@manjuggm)

Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study. Talk by Dr. Antonio Avallone, MD #ASCO22 #CRCSM (@manjuggm)

I think @ChiaraCrem1 did an amazing job from the plenary stage presenting colon cancer as a group of molecularly and anatomically defined subsets: for instance the PARADIGM data apply best to LEFT-sided, ras wildtype, MSS, braf wildtype tumors #asco22 #crcsm (@marklewismd)

Reinhard Dummer presents TRICOTEL trial for #melanoma brain mets. Two tx cohorts based on BRAF status. BRAF wt (cohort 2) recieved BRAF/MEK/PDL1. ORR 42%. No diff if symptomatic. 70% gr 3/4 tox for triple tx. (@OlofssonBagge)

Reinhard Dummer presents TRICOTEL trial for #melanoma brain mets. Two tx cohorts based on BRAF status. BRAF wt (cohort 2) recieved BRAF/MEK/PDL1. ORR 42%. No diff if symptomatic. 70% gr 3/4 tox for triple tx. #ASCO22 (@OlofssonBagge)

Dr Drummer presenting TRICOTEL for the first time. Vemurafenib+ cobimetinib+ atezolizumab for #melanoma with CNS Mets. Cohort 1 (BRAF WT closer early) but Cohort 2 continued. Important: trial INCLUDED patients who required steroids! #ASCO22 @OncoAlert (@DrBetofMDPhD)